Placebo ASP8062

DRUG2 trials

Sponsors

Astellas Pharma Global Development, Inc.

Conditions

Opioid Use Disorder

Phase 1

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

CompletedNCT04447287

Astellas Pharma Global Development, Inc.Opioid Use Disorder

Start: 2020-06-29End: 2020-11-25Updated: 2024-11-21

Phase 2

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

WithdrawnNCT05062577

Astellas Pharma Global Development, Inc.Opioid Use Disorder

Start: 2021-11-08End: 2023-02-28Updated: 2024-11-06

Related Papers

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder

Journal of Psychopharmacology2023-02-013 citations